Silver Mines Limited (ASX: SVL)
Silver Mines Limited (ASX: SVL) explores, discovers, and develops silver mining operations in Australia and overseas.
The company has via the latest release on ASX disclosed the details about its activities for the quarter ended 31 December 2018. A snippet indicating highlights for the quarter ended are as follows:
- During the quarter, the drilling got commenced at the Barabolar Project, in New South Wales. Few of the very high-priority targets were identified for drilling, which was based on the geochemistry and geological mapping data.
- By the end of the quarter, 8 RC drill holes were completed, making for around 1,615 meters. The mineralization and alteration are indicative of being proximal epithermal/porphyry systems, and hence an exceptional porphyry and polymetallic epithermal targets for further drills. The various specific drill targets during the quarter included the following:
- Copper-silver-lead-zinc (+gold) polymetallic systems discovered at the Bara Mine & Bara North Prospects.
- Epithermal gold systems, which was found at the Cringle Prospect where surface sampling showed signs of high-grade gold and silver.
- Porphyry copper-gold targets were located at the various locations highlighted by strong anomalies.
Post the end of this quarter, the Company’s subsidiary Bowdens Agriculture Pty Ltd entered a pact for availing the financing facility for $1,010,000 with the Westpac Banking Corporation. The facility has been provided for purchasing the agricultural land, which would be in proximity to the Bowdens Silver Project and conjunction with the land requirements as part of future mining activities.
Now let us quickly look at the company’s stock performance over the last few months. The stock is last traded at $ 0.054, with a market capitalization of circa $34.61 Mn as on 25 Jan. 2019. The stock has delivered a YTD return of -5.26%. The company has posted returns of 38.97%, and 22.73% over the last six months & three months period respectively, as on 25 January 2019. It has a 52-week high price of $0.088 and a 52-week low of $0.024, with an average volume of 2,061,922 approximately.
BARD1 Life Sciences Limited (ASX: BD1)
BARD1 Life Sciences Limited (ASX: BD1) has via the latest release on ASX disclosed the details about its activities for the quarter ended 31 December 2018. A snippet indicating highlights for the quarter ended are as follows:
- Company’s closing cash balance stood at $3.7m as at the end of the quarter. The cash outflow from the operations came in at $542k, of which Research and Development (R&D) expenditure of $131k was attributed to the BARD1 pipeline project.
- BARD1-Breast Cancer Test: World-first BARD1-Breast cancer test showed the signs of high accuracy for detection of breast cancer with 70% sensitivity and 88% specificity. This study was validated via an independent sample of breast lesions; it showed the difference clearly between the malignant breast cancer and benign lesions.
- Assay development program: The feasibility was completed during the quarter, and now the development phase has begun.
- The Chinese divisional patent was granted by the CNIPA providing additional protection for BARD1-Lung isoforms in lungs and colorectal cancer.
- During the quarter, the company successfully raised an amount of $3.315m via an issue of 165,732,775 New Shares at an issue price of $0.02 per share. The funds raised from the issue are slated to be utilized for advanced development of the BARD1 diagnostics pipeline.
Now let us quickly look at the company’s stock performance over the last few months. The stock is last traded at $ 0.022, with a market capitalization of circa $20.88 Mn as on 28 Jan. 2019. The company has posted returns of 49.92%, and -39.22% over the last six months & three months period respectively, as on 25 January 2019. It has a 52-week high price of $0.073 and a 52-week low of 0.010, with an average volume of 23,362,568 approximately.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.